Literature DB >> 2189101

Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.

G V Bhat1, H M Temin.   

Abstract

Reticuloendotheliosis virus strain T (Rev-T) is a highly oncogenic retrovirus that induces a lethal lymphoma in young galliform birds and also transforms and immortalizes avian lymphoid cells in vitro. Rev-T presumably arose when a reticuloendotheliosis virus (Rev) incorporated a portion of the turkey c-rel gene into its genome, forming the v-rel oncogene. The predicted v-rel protein (p59v-rel) has 14 amino acid substitutions and 3 amino acid deletions relative to the predicted turkey c-rel protein. The 5' Rev env-derived amino-terminus of p59v-rel also has amino acid substitutions in codons 3, 6, and 9 relative to wild-type Rev-A env. To distinguish the critical alterations from the neutral ones, we made a mutation that resulted in a substitution of the 5' Rev env-derived amino-terminus by a single methionine, as well as several back-mutations, in the context of an otherwise wild-type v-rel and tested the transforming, immortalizing, and tumorigenic properties of the resulting proteins. All proteins tested retained the transforming, immortalizing, and tumorigenic functions of v-rel. Absence of the 5' Rev env-derived amino-terminus, as well as back-mutations of six of the amino acid changes present in the rel-derived amino-terminal and central regions of v-rel, reduced transformation efficiency. The mutations present in codons 3, 6, and 9 of p59v-rel showed complicated interactions in their activating effects on transformation efficiency. We also showed that loss of the immortalizing function did not abolish tumorigenesis by v-rel. We further showed that the primary transduction event involving the turkey c-rel gene could have occurred with a replication-competent Rev having v-rel-specific mutations in codons 3, 6, and 9 of the env gene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2189101

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The RxxRxRxxC motif conserved in all Rel/kappa B proteins is essential for the DNA-binding activity and redox regulation of the v-Rel oncoprotein.

Authors:  S Kumar; A B Rabson; C Gélinas
Journal:  Mol Cell Biol       Date:  1992-07       Impact factor: 4.272

2.  Differential pp40I kappa B-beta inhibition of DNA binding by rel proteins.

Authors:  J A Diehl; T A McKinsey; M Hannink
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

3.  Evolution of the oncogenic potential of v-rel: rel-induced expression of immunoregulatory receptors correlates with tumor development and in vitro transformation.

Authors:  J Nehyba; R Hrdlicková; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

4.  The relocalization of v-Rel from the nucleus to the cytoplasm coincides with induction of expression of Ikba and nfkb1 and stabilization of I kappa B-alpha.

Authors:  R Hrdlicková; J Nehyba; A Roy; E H Humphries; H R Bose
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

5.  The v-rel oncogene promotes malignant T-cell leukemia/lymphoma in transgenic mice.

Authors:  D Carrasco; C A Rizzo; K Dorfman; R Bravo
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

6.  Mapping of a serine-rich domain essential for the transcriptional, antiapoptotic, and transforming activities of the v-Rel oncoprotein.

Authors:  C Chen; F Agnès; C Gélinas
Journal:  Mol Cell Biol       Date:  1999-01       Impact factor: 4.272

7.  A mutant v-rel with increased ability to transform B lymphocytes.

Authors:  P Romero; E H Humphries
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

8.  In vivo evolution of c-rel oncogenic potential.

Authors:  R Hrdlicková; J Nehyba; E H Humphries
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

9.  Mutations in the DNA-binding and dimerization domains of v-Rel are responsible for altered kappa B DNA-binding complexes in transformed cells.

Authors:  R Hrdlicková; J Nehyba; H R Bose
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.